Jan Rosenbaum is a seasoned executive in the biotechnology and pharmaceutical sectors, currently serving as the President, Chief Executive Officer, and Chief Scientific Officer of Kurome Therapeutics, Inc. since February 2020, where the focus is on developing innovative cancer therapies. In addition, Jan contributes as a Business Development Advisor to the Harrington Discovery Institute, offering support for drug development initiatives. As the Founder and President of BRK-1 Technical Advisors, Jan specializes in commercialization strategies for novel technologies. Educationally, Jan holds a Ph.D. in Pharmaceutical Chemistry from the University of California, San Francisco, and has served in various academic roles, including as a Visiting Scholar at the University of Cincinnati and as an Adjunct Professor at The Ohio State University. With extensive experience in consulting and leadership roles, Jan has been instrumental in advancing therapeutic development in multiple capacities throughout a distinguished career.
This person is not in any teams
Harrington Discovery Institute at University Hospitals
The Harrington Discovery Institute at University Hospitals in Cleveland, OH – part of The Harrington Project for Discovery & Development – aims to advance medicine and society by enabling our nation’s most inventive scientists to turn their discoveries into medicines that improve human health. Harrington Discovery Institute was created in 2012 with a $50 million founding gift from the Harrington family and instantiates the commitment they share with University Hospitals to a Vision for a ‘Better World’.